Novavax, Inc. (NVAX) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Stay updated on Novavax, Inc. (NVAX) stock with short-term forecast for year 2025 and long-term price prediction for 2025 - 2050. Access historical performance, see analyst ratings, and follow the latest Novavax, Inc. news and developments.
1 Month Prediction
$16.59 [78.07%]
3 Month Prediction
$16.26 [74.57%]
6 Month Prediction
$25.32 [171.87%]
1 Year Prediction
$21.41 [129.89%]
3 Year Prediction
$33.15 [255.83%]
5 Year Prediction
$44.88 [381.77%]
About Novavax, Inc.
Novavax, Inc. is an American biotechnology company that develops vaccines to counter serious infectious diseases. Founded in 1987, the company has approx. 1,543 employees.
Novavax initially focused on developing vaccines for influenza and respiratory syncytial virus (RSV), as well as for Ebola and other emerging infectious diseases. The company gained attention during COVID-19 for its development of NVX-CoV2373 vaccine, which was later branded as Nuvaxovid.
Novavax has its research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. The company has been involved in various clinical trials to assess the efficacy of its vaccines. Notably, it reported a 90.4% efficacy rate for its COVID-19 vaccine in Phase 3 trials conducted in the U.S. and Mexico.
Novavax, Inc. (NVAX) Historical Performance
IPO Date
Novavax, Inc. (NASDAQ:NVAX) went public on 05 December, 1995.
Change
Since inception, NVAX has decreased by 90.19%. In the last 5 years, NVAX has fallen from $16.00 to $9.31, a massive -41.78% decrease since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $238.54 and a low of $4.00.
52 Week Range
$3.53
$23.86
The current price $9.31 is not near the 52-week extremes, which means that the stock is neither overbought nor underbought.
NVAX Stock Price History
Based on NVAX stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the NVAX stock has risen from $7.62 - $143.1 to $9.31 - $9.31, which is up 35.39%. Currently, the stock follows upward trend.
Here, we have calculated stock range of NVAX, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $7.62 - $143.1 | $73.19 | 964.37 | 1 Year Change |
| 2021 | $143.07 - $238.54 | $196.34 | 2755.29 | 2 Year Change |
| 2022 | $10.28 - $93.7 | $46.45 | 575.5 | 3 Year Change |
| 2023 | $4.8 - $10.91 | $7.64 | 11.11 | 4 Year Change |
| 2024 | $4.0 - $15.03 | $9.16 | 33.21 | 5 Year Change |
| 2025 | $9.31 - $9.31 | $9.31 | 35.39 | 6 Year Change |
NVAX Price Performance
6-Month Performance
NVAX stock dropped by 24.76% in the last six months.
1-Year Performance
The stock has trended upwards by 88.56% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 88.83%.
5-Year Performance
In the last 5 years, the stock has gone down by 41.78%.
According to Novavax, Inc.'s historical data, below graph gives us the exact picture of how the NVAX stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 3 years and a decline in 2 years.
2020
2,701.76% ↑
2021
28.30% ↑
2022
92.81% ↓
2023
53.31% ↓
2024
67.50% ↑
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Novavax, Inc. (NVAX) Financials & Stock Analysis
Total Revenue
Quarterly Revenue: $84.51 M (Q3)
Revenue for Q3 ending 30th September, 2024 decreased 79.66% compared to Q2 ending 30th June, 2024.
Annual Revenue: $847.25 M (1Y)
Revenue for trailing 12 months increased 52.28% year over year from 31st December, 2023.
If compared to the last 5 years, the revenue has gone up from $22.39 million to $847.25 million, a 3,684.39% change.
Market Capitalization
Novavax, Inc. has a market capitalization of $1.49B, which places NVAX in the small-cap category.
Fundamental Analysis
EPS: $-0.76 (Q3), $-5.41 (1Y)
EPS decreased 169.72% since last quarter, and decreased 35.75% since last year.
Net Income: $-121.30 M (Q3), $-545.06 M (1Y)
Net Income decreased 174.70% since last quarter, and decreased 17.16% since last year.
Free Cash Flow: $-146.83 M (Q3), $-772.77 M (1Y)
Free Cash Flow decreased 147.19% since last quarter, and increased 51.85% since last year.
Net Profit Margin: -143.53% (Q3), -64.33% (1Y)
Net Profit Margin decreased 467.25% since last quarter, and decreased 45.60% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for NVAX stock. These indicators help you understand Novavax, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for NVAX stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $8.90 |
| SMA50 | $8.77 |
| SMA200 | $10.74 |
| RSI | 56.54 |
| Beta | 2.09 |
SMA20 < Current Price
This signals NVAX stock is in short-term bullish momentum.
SMA50 < Current Price
This signals NVAX stock is in mid-term bullish momentum.
SMA200 > Current Price
This signals NVAX stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for NVAX stock is Neutral. Out of all indicators, 2 indicates bullish signals, 3 signals bearish trends and 4 gives neutral trends. The NVAX stock forecast was last updated on 11 January, 2025.
Novavax, Inc. (NVAX) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $22.09 by the end of 2025, and can reach around $24.46 to $9.15 in 2026. And, the long-term forecast suggests that the stock may further drop to $14.25 - $-5.33 in 2028, and $57.49 - $22.38 by 2031. So, the NVAX stock shows a strong upward trend in the next several years.
Short-term NVAX Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-02 | $16.59 | 78.1% |
| 2025-03 | $16.57 | 77.89% |
| 2025-04 | $16.26 | 74.56% |
| 2025-05 | $27.19 | 191.89% |
| 2025-06 | $25.04 | 168.81% |
| 2025-07 | $25.32 | 171.82% |
| 2025-08 | $23.50 | 152.28% |
| 2025-09 | $23.50 | 152.28% |
| 2025-10 | $23.63 | 153.68% |
| 2025-11 | $22.81 | 144.87% |
| 2025-12 | $22.09 | 137.14% |
In 2025, the NVAX stock price is expected to fluctuate between $16.26 and $27.19. According to the monthly forecast, the stock could rise to $22.09 by December 2024. If compared to the NVAX's current price, the stock could gain 137.14% by the end of this year.
Long-term NVAX Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $24.46 | $44.76 | $9.15 | -1.77% |
| 2027 | $12.55 | $36.00 | $34.48 | 270.16% |
| 2028 | $14.25 | $50.35 | $-5.33 | -157.22% |
| 2029 | $53.88 | $77.54 | $47.27 | 407.46% |
| 2030 | $19.13 | $35.94 | $38.23 | 310.41% |
| 2031 | $57.49 | $60.14 | $22.38 | 140.26% |
| 2032 | $53.30 | $66.91 | $37.01 | 297.32% |
| 2033 | $37.30 | $52.19 | $80.27 | 761.73% |
| 2034 | $53.97 | $-16.11 | $102.10 | 996.08% |
| 2035 | $66.02 | $86.20 | $24.50 | 163.02% |
| 2036 | $108.73 | $74.69 | $115.71 | 1142.19% |
| 2037 | $66.26 | $132.74 | $103.17 | 1007.57% |
| 2038 | $82.80 | $75.97 | $104.75 | 1024.53% |
| 2039 | $107.27 | $66.41 | $1.94 | -79.17% |
| 2040 | $93.18 | $165.01 | $130.94 | 1305.69% |
| 2041 | $179.05 | $223.28 | $95.17 | 921.69% |
| 2042 | $18.06 | $113.77 | $210.81 | 2163.12% |
| 2043 | $112.19 | $37.01 | $134.64 | 1345.41% |
| 2044 | $155.11 | $118.10 | $32.70 | 251.05% |
| 2045 | $228.92 | $49.72 | $282.62 | 2934.03% |
| 2046 | $148.08 | $118.52 | $234.35 | 2415.83% |
| 2047 | $146.22 | $322.51 | $133.51 | 1333.28% |
| 2048 | $94.91 | $148.54 | $94.51 | 914.6% |
| 2049 | $257.05 | $27.17 | $25.82 | 177.19% |
| 2050 | $149.33 | $123.47 | $185.05 | 1886.58% |
| 2051 | $92.58 | $224.04 | $169.50 | 1719.65% |
Novavax, Inc. (NVAX) Stock Price Prediction & Forecast 2025
At the start of 2025, the NVAX stock was at $9.31. Today, it is trading at $9.31, which is 0.00% increase from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $22.09 by December 2025 with a 137.14% change.
Novavax, Inc. (NVAX) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant appreciation in the NVAX stock. During this period, the NVAX's price is forecasted to shift from $24.46 to $38.23, which is 56.30% gain.
In 2026, the stock would possibly open at $24.46, escalates to $44.76 by mid-year, and wraps up at $9.15, reflecting a decrease from today's price. Further moving to 2030, the stock can kick off the year at $19.13, soar to $35.94 by mid-year, and finish at $38.23, which is 310.41% change from current price.
Novavax, Inc. (NVAX) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $57.49 to $130.94, which is up 140.21%
In 2031, we can expect NVAX to fluctuate between $22.38 and $57.49, a shift indicating a 140.21% gain by year-end compared to current price. And Until 2040, NVAX can likely vary from $93.18 to $130.94. By the end of 2040, the stock could record a 1305.67% rise from today's stock price.
Novavax, Inc. (NVAX) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the NVAX stock can see an an upturn from $179.05 to $185.05 in this period. In 2041, the stock can experience a high of $223.28 by mid-year, closing the year at $95.17. This results in a 2297.00% increase from today.
Moving towards the end of 2050, NVAX is projected to open the year at $149.33. The stock may dip to $123.47 during mid-year and finish the year at $185.05. Compared to the stock's current price, this translates to an overall gain of 1886.58% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
NVAX Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| HOTH | Hoth Therapeutics, Inc. | - | $2.47 | 0.00% ▼ | -23.28 ▼ |
| SANA | Sana Biotechnology, Inc. | - | $4.49 | -0.11% ▼ | $225.59 ▲ |
| NRXP | NRx Pharmaceuticals, Inc. | - | $4.52 | 0.00% ▼ | -12.84 ▼ |
| OTLK | Outlook Therapeutics, Inc. | - | $1.47 | -28.29% ▼ | $648.24 ▲ |
| CABA | Cabaletta Bio, Inc. | - | $2.34 | -38.74% ▼ | $769.02 ▲ |
Last updated Jan 11 at 12:56 AM
NVAX : Buy, Sell Or Hold?
Analyst Ratings
Based on 5 analysts, 1 rated as a strong buy, 1 recommended a buy, 2 suggested a hold, 0 advised a sell, and 1 indicated a strong sell.Three months ago, out of 4 analysts, 0 analysts gave a strong buy rating, 2 a buy rating, 1 a hold rating, 0 advised selling, and 1 suggested a strong sell.So, according to analyst ratings, the recommendation for NVAX stock is Buy.
Expert Analysis
According to NVAX short-term and long-term forecast, Novavax, Inc. shares are projected to go up by 1886.58%, and reach a value of $185.05 per share by 2050.
As per technical analysis, indicators show a Neutral sentiment, while Fear & Greed Index stands at 42.857142857142854, which signals Fear. Also, NVAX has recorded 10/30 green days, which reflects a 50.0% positivity rate with a price volatility of 0.05%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that NVAX stock is undervalued. So, Based on NVAX prediction and analysis, it may be the best time to hold NVAX stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "NVAX” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.